Investigators confirmed checkpoint pathway modulation by evaluating surrogate markers in tumour tissue treated with AZD7762, demonstrating decreased autophosphorylation of Chk1 at serine 296, and increased γH2AX. This evidence concerns the gene CHEK1 and neoplasm.